DealForma Research

Recent Articles

M&A – Biopharma Therapeutics & Platforms – Q1 2024

April 23, 2024

Healthcare & Life Sciences Quarterly Overview – Q1 2024

April 18, 2024

R&D Partnerships, M&A, Ventures & IPOs by TA – Autoimmune – 2023

April 10, 2024

R&D Partnerships, M&A, Ventures & IPOs by TA – Neurologic – 2023

March 28, 2024

R&D Partnerships, M&A, IPOs, Ventures – Medtech, Device, Digital Health, Wearables

March 28, 2024

IPOs – Biopharma Therapeutics & Platforms – 2023

March 27, 2024

Ventures – Biopharma Therapeutics & Platforms – 2023

March 26, 2024

M&A – Biopharma Therapeutics & Platforms – 2023

March 26, 2024

R&D Partnerships – Biopharma Therapeutics & Platforms – 2023

March 26, 2024

IPO Activity In Global Healthcare & Life Sciences

March 22, 2024

R&D Partnerships, M&A, Ventures, & IPOs By TA – Cancer – 2023

March 21, 2024

January 2024 Top Biopharma Deal: Argo and Novartis for RNA-based therapies

February 7, 2024

Inpart’s and DealForma’s Predictions for Biopharma Dealmaking in 2024

February 6, 2024

All of this by stage, disease indication, modality, target…

+ 0 k

Licensing Deals

+ 0 k

M&A

+ 0 k

Other Deals

+ 0 k

Funding Rounds

+ 0 k

Company Profiles

+ 0 k

Drug Sales Figures